Compare Fidelity National Information Servcs Inc (FIS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs IDEXX Laboratories, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $41.63 (market cap $22.05B), while IDEXX Laboratories, Inc. trades at $570.64 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.1× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FIS | IDXX | |
|---|---|---|
Market Cap | $22.05B | $46.22B |
Sector | Technology | Health |
52-Week High | $72.77 | $766.68 |
52-Week Low | $37.72 | $526.44 |
Enterprise Value | $42.56B | $47.12B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $41.64, down 2.05% today, with technical indicators showing bearish momentum despite attractive valuation metrics including a P/E of 6.57 and P/S of 1.82. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, while lowering full-year guidance due to capital markets weakness. Recent developments include global expansion of Digital One Commercial platform and recognition as world's best treasury management software.
FIS presents a compelling value opportunity with strong banking solutions growth and improving cash flow, though near-term headwinds in capital markets create uncertainty. The stock trades at a discount to analyst consensus target of $50.18, with 58% of analysts maintaining buy ratings, suggesting potential upside if execution improves.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
